Celldex Therapeutics, Inc. Recap

What is your opinion of Celldex Therapeutics, Inc.?

Celldex Therapeutics, Inc.

NASDAQ:CLDX - Sep. 3rd 11:21pm

$ 13.93 -0.88 (-5.94%)

Shares of Celldex Therapeutics, Inc. – a $1.2 billion market cap Pharmaceuticals company – have fallen -5.94 percent to $13.93 as of 8:58 PM. With the current share price, Celldex Therapeutics, Inc. has a P/E Ratio of 0.00.

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.

Find out more about Celldex Therapeutics, Inc..


Celldex Therapeutics, Inc. Hit a 52-week High

Celldex Therapeutics, Inc. (NASDAQ:CLDX) hit a 52-week share price high of $32.82.

HAMPTON, NJ | 5 months ago

Financials
Celldex Therapeutics, Inc.